The Rancho Bernardo study was the first long-term study to corroborate the usefulness of adiponectin as a biomarker in coronary heart disease (CHD), demonstrating that higher ApN levels were associated with a favorable cardiovascular risk profile in both sexes from the same population [61]. The gene discussed is ADIPOQ; the disease is coronary artery disorder.